STAT+: Amgen’s Repatha linked to fewer heart attacks

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pithy intro text about the biopharma milieu. 

Novartis cites more tumor reports after Zolgensma

Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy for spinal muscular atrophy. The company has received nine tumor reports in all since the treatment was approved in 2019, STAT’s Ed Silverman and Jason Mast write. 

Continue to STAT+ to read the full story…